文献速递前列腺癌

磁共振成像引导的外照射放疗对前列腺内病灶进行局灶加量治疗局限性前列腺癌:系统综述与Meta分析

Magnetic Resonance Imaging-guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2022-10-27

本系统综述与Meta分析纳入17项前瞻性研究共1290例局限性前列腺癌患者,评估磁共振成像引导外照射放疗对前列腺内病灶局灶加量的临床结局。结果显示急性和晚期胃肠道及泌尿生殖道毒性均较低,总体生化无病生存率为95.0%(95%CI 91.9-97.4%),结论认为该方案可行且安全,但超分割和超大分割仍需进一步研究。

要点

  • 17项研究共1290例患者,急性≥2级胃肠道毒性7.5%,晚期≥2级7.0%。
  • 急性≥2级泌尿生殖道毒性29.5%,晚期≥2级16.0%。
  • 总体生化无病生存率95.0%(95%CI 91.9-97.4%)。

核心结论

  • 磁共振成像引导的外照射放疗对前列腺内病灶局灶加量治疗局限性前列腺癌可行且安全,胃肠道和泌尿生殖道毒性低,生化疾病结局良好。
  • 1级证据支持该方案在标准分割下较全前列腺照射具有更优的生化无病生存率;但超分割和超大分割仍需进一步研究。

研究设计与样本

  • 系统综述与Meta分析,遵循系统综述和Meta分析优先报告条目(PRISMA)指南,由三名独立评审员检索三个数据库。
  • 纳入标准为2000年至2021年发表的英文原创文章,前瞻性研究,局限性前列腺癌患者(n>10)接受磁共振成像引导的外照射放疗对前列腺内病灶局灶加量。
  • 共纳入17项研究,1290例患者。
  • 采用加权随机效应Meta分析,使用I2统计量评估异质性,通过漏斗图评估发表偏倚。

主要发现

  • 患者风险类别存在异质性:低危63例,中危532例,高危695例;磁共振成像使用及治疗计划和实施亦存在异质性。
  • 急性/晚期累积≥2级胃肠道毒性估计率分别为7.5%/7.0%(95%CI 4.0-12.1%/2.8-12.8%)。
  • 急性/晚期累积≥3级胃肠道毒性估计率分别为0.1%/0.2%(95%CI 0-0.4%/0-1.1%)。
  • 急性/晚期≥2级泌尿生殖道毒性分别为29.5%/16.0%(95%CI 17.6-43.0%/8.3-25.7%)。
  • 急性/晚期≥3级泌尿生殖道毒性分别为0.4%/1.3%(95%CI 0.0-1.3%/0.3-3.0%)。

关键数值与推荐

  • 随访>5年的局灶加量研究患者中,生化无病生存率为92.4%(95%CI 84.5-97.7%)。
  • 无论随访时长,总体生化无病生存率为95.0%(95%CI 91.9-97.4%)。
  • 所有研究均报告良好的安全性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 患者风险类别存在异质性(低危63例,中危532例,高危695例)。
  • 磁共振成像使用及治疗计划和实施存在异质性。
  • 超分割和超大分割仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It is anticipated that a focal boost to intraprostatic lesions (IPLs) using external beam radiotherapy (EBRT) guided by magnetic resonance imaging (MRI) will increase biochemical disease-free survival (bDFS) without increasing toxicity in the treatment of localized prostate cancer (PC). OBJECTIVE: To systematically review clinical outcomes for MRI-guided EBRT focal boost to IPLs. EVIDENCE ACQUISITION: Three independent reviewers conducted literature searches in three databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. The inclusion criteria were original English-language articles from 2000 to 2021 on prospective studies of patients with localized PC (n > 10) receiving an MRI-guided EBRT focal boost to IPLs. The main outcomes and measures were safety, gastrointestinal (GI)/genitourinary (GU) toxicities, quality of life, and biochemical disease outcomes. Weighted random-effects meta-analyses were conducted. Heterogeneity was assessed using the I2 statistic. Publication bias was assessed via funnel plots. EVIDENCE SYNTHESIS: Seventeen studies (1290 patients) were included. There were heterogeneities in patient risk category (low risk, 63; intermediate risk, 532; high risk, 695), MRI utilization, and treatment planning and delivery. All studies reported good safety, with estimated rates of 7.5%/7.0% (95% confidence interval [CI] 4.0-12.1%/2.8-12.8%) and 0.1%/0.2% (95% CI 0-0.4%/0-1.1%) for acute/late cumulative grade ≥2 and grade ≥3 gastrointestinal toxicities, and 29.5%/16.0% (95% CI 17.6-43.0%/8.3-25.7%) and 0.4%/1.3% (95% CI 0.0-1.3%/0.3-3.0%) for acute/late grade ≥2 and grade ≥3 genitourinary toxicities, respectively. Across patients in focal boost studies with follow-up >5 yr, bDFS was 92.4% (95% CI 84.5-97.7%). The overall bDFS was 95.0% (95% CI 91.9-97.4%) regardless of follow-up duration. CONCLUSIONS: MRI-guided EBRT focal boost to IPLs in localized PC was feasible and safe, with low GI/GU toxicities and favorable biochemical disease outcomes. Level 1 evidence supports the superior bDFS of this approach over whole-prostate irradiation for standard fractionation; however, further research is required for hypofractionation and ultra-hypofractionation. PATIENT SUMMARY: We reviewed 17 studies on the use of magnetic resonance imaging (MRI)-guided radiotherapy with delivery of a higher radiation level to lesions within the prostate that were visible on MRI. This approach was well tolerated and might offer better disease control in prostate cancer over traditional radiotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Poon DMC, Yuan J, Yang B, et al. Magnetic Resonance Imaging-guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2022. PMID: 41429687. doi:10.1016/j.euo.2022.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。